Your browser doesn't support javascript.
loading
Adverse events with quetiapine and clarithromycin coprescription: A population-based retrospective cohort study.
Yau, Kevin; McArthur, Eric; Jeyakumar, Nivethika; Tsobo Muanda, Flory; Kim, Richard B; Clemens, Kristin K; Wald, Ron; Garg, Amit X.
Affiliation
  • Yau K; Division of Nephrology Temerty Faculty of Medicine Toronto Ontario Canada.
  • McArthur E; Institute for Clinical Evaluative Sciences Ontario Canada.
  • Jeyakumar N; London Health Sciences Centre Lawson Health Research Institute London Ontario Canada.
  • Tsobo Muanda F; Institute for Clinical Evaluative Sciences Ontario Canada.
  • Kim RB; London Health Sciences Centre Lawson Health Research Institute London Ontario Canada.
  • Clemens KK; Institute for Clinical Evaluative Sciences Ontario Canada.
  • Wald R; Department of Physiology & Pharmacology Western University London Ontario Canada.
  • Garg AX; London Health Sciences Centre Lawson Health Research Institute London Ontario Canada.
Health Sci Rep ; 6(6): e1375, 2023 Jun.
Article in En | MEDLINE | ID: mdl-37359413
ABSTRACT
Background and

Aims:

Quetiapine is an atypical antipsychotic predominantly metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. We studied the risk of adverse events following coprescription of clarithromycin (a strong CYP3A4 inhibitor) versus azithromycin (not a CYP3A4 inhibitor) in quetiapine users. Materials and

Methods:

This was a population-based retrospective cohort study from 2004 to 2020 in Ontario, Canada in adult quetiapine users newly co-prescribed clarithromycin (n = 16,909) or azithromycin (n = 25,267). The primary outcome was the composite of hospital encounters with encephalopathy (defined as a diagnosis of delirium, disorientation, transient alteration of awareness, transient ischemic attack, or unspecified dementia), a fall, or a fracture within 30 days of new coprescription. Secondary outcomes were individual components of the composite outcome, hospital encounter with computed tomography (CT) head scan, and all-cause mortality.

Results:

Coprescription of clarithromycin versus azithromycin with quetiapine was associated with a higher risk of the primary composite outcome (365 of 16,909 clarithromycin users [2.2%] vs. 309 of 16,929 azithromycin users [1.8%]; absolute risk increase, 0.34% [95% confidence interval, CI, 0.04-0.63]; relative risk [RR], 1.19 [95% CI, 1.02-1.38]). This was primarily driven by an increase in fragility fractures (78 of 16,909 clarithromycin users [0.5%] vs. 45 of 16,923 azithromycin users [0.3%]; absolute risk increase, 0.20% [95% CI, 0.07-0.32]; RR, 1.74 [95% CI, 1.21-2.52]). Hospital encounters with a CT head scan were higher in clarithromycin users (220 of 16,909 [1.3%] vs. 175 of 16,923 azithromycin users [1.0%]; absolute risk increase, 0.27% [95% CI, 0.04-0.50]; RR, 1.26 [95% CI, 1.04-1.54]), but there was no difference in hospital encounters with encephalopathy, falls, or all-cause mortality between macrolide groups.

Conclusion:

Among adults taking quetiapine, concurrent use of clarithromycin compared with azithromycin was associated with a small but statistically greater 30-day risk of a hospital encounter for encephalopathy, falls, or fracture, which was predominantly related to a higher rate of fragility fractures.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Language: En Journal: Health Sci Rep Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Language: En Journal: Health Sci Rep Year: 2023 Document type: Article